Pembrolizumab vs Rituximab

## Pembrolizumab vs Rituximab: Overview

This comparison examines the pharmacological differences between **Pembrolizumab** and **Rituximab**.

## Mechanism of Action

**Pembrolizumab**: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

**Rituximab**: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

## Pharmacokinetics

**Half-life**: Pembrolizumab — 26 days; Rituximab — 22 days.

## Chemical Properties

**Type**: Pembrolizumab — Antibody; Rituximab — Antibody.